OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________________ FORM 10-Q ____________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2025 (S ...

Core Insights - Veeva Systems has announced a collaboration with Amgen to enhance clinical trial innovation, utilizing the Veeva Clinical Platform to improve efficiencies in the clinical trial process [1][2][3] Group 1: Collaboration Details - Amgen aims to leverage advanced technology through this collaboration to enhance its end-to-end trial operations, which is expected to expedite the delivery of innovative treatments to patients [2] - The Veeva Clinical Platform will serve as the backbone for standardized and connected processes, facilitating faster delivery of life-saving drugs [3] Group 2: Veeva Clinical Platform Overview - The Veeva Clinical Platform is a comprehensive and connected solution that encompasses various clinical operations and data applications, including CTMS, EDC, clinical workbench, RTSM, eCOA, eTMF, and more [4] - This platform is designed to streamline clinical trials from initiation to completion, automating data flow and enhancing operational efficiency [4] Group 3: Company Background - Veeva Systems provides industry-specific cloud solutions for life sciences, serving over 1,500 customers, including major biopharmaceutical companies and emerging biotech firms [5] - The company is committed to innovation, product excellence, and balancing the interests of all stakeholders, including customers, employees, and shareholders [5]

Veeva Systems (VEEV) Q2 2026 Earnings Call August 27, 2025 05:00 PM ET Company ParticipantsGunnar Hansen - Director of IRPeter Gassner - Founder, CEO & DirectorBrian Van Wagener - CFOPaul Shawah - EVP, Commercial StrategyBrian Peterson - Managing DirectorDavid Windley - Managing DirectorRishi Jaluria - MD & Software Equity ResearchCraig Hettenbach - Executive DirectorJailendra Singh - Managing DirectorSaket Kalia - Managing DirectorJeff Garro - Managing DirectorDavid Larsen - Managing DirectorConference Cal ...

Financial Data and Key Metrics Changes - Total revenue for the quarter was $789 million, with non-GAAP operating income of $353 million, exceeding guidance [6][7]. - The company expressed confidence in its $6 billion revenue plan over the next five years, indicating strong performance and growth potential [22]. Business Line Data and Key Metrics Changes - R&D subscriptions and services showed significant upside, indicating a broad-based growth across all areas [19][40]. - The resolution of the lawsuit with IQVIA is expected to enhance the commercial cloud offerings, particularly in integrating IQVIA data into Veeva's products [12][14]. Market Data and Key Metrics Changes - The company reported strong execution across its business segments, with no specific areas of weakness despite macroeconomic uncertainties [124]. - The commercial cloud segment is anticipated to benefit from the resolution with IQVIA, allowing for a more comprehensive solution for customers [73][86]. Company Strategy and Development Direction - Veeva is focusing on enhancing its AI capabilities, with plans to integrate AI agents into its existing platforms, which is expected to create significant value for the industry over time [28][30]. - The company aims to leverage its structural advantages in the life sciences sector to lead in industry-specific cloud applications and AI agents [46][48]. Management's Comments on Operating Environment and Future Outlook - Management noted that while there is elevated uncertainty in the macro environment, customer engagement remains strong, and the pipeline is building effectively [124]. - The company does not expect immediate revenue contributions from the IQVIA resolution but sees it as a long-term growth driver [90]. Other Important Information - The company is working on refining its migration tooling to facilitate customer transitions to the Vault CRM, with over 20 customers already migrated and 300 more planned [106]. - Veeva's business consulting services are seen as a critical component in driving AI adoption and helping customers navigate changes in workflows [111][115]. Q&A Session Summary Question: What led to the resolution of the lawsuit with IQVIA? - The resolution was driven by changes in the industry landscape and a mutual recognition that collaboration would benefit both companies and their customers [12][14]. Question: How does the resolution with IQVIA unlock new opportunities? - It removes previous barriers to integrating IQVIA data into Veeva's products, enhancing the commercial cloud offerings and allowing for more comprehensive solutions [14][73]. Question: What is the outlook for R&D subscription growth? - R&D subscriptions are expected to continue growing, supported by strong execution across all areas and a stable environment [40][76]. Question: How does Veeva plan to leverage AI in its offerings? - Veeva plans to integrate AI agents into its platforms, enhancing productivity and creating new revenue opportunities over time [28][30]. Question: What is the customer reaction to the IQVIA resolution? - Customer feedback has been overwhelmingly positive, as the resolution alleviates previous integration issues and opens up new possibilities for collaboration [34][36]. Question: What are the expectations for commercial subscriptions moving forward? - The company anticipates continued strength in commercial subscriptions, particularly driven by the Crossix product, despite some flatness in the recent quarter [74][76]. Question: How does Veeva differentiate itself in the AI space? - Veeva's structural advantage lies in its deep industry-specific applications, allowing for seamless integration of AI agents into existing workflows [94][96].

Q2'26 Quarterly Results August 27, 2025 Safe Harbor and Other Information This presentation and associated commentary contain forward-looking statements regarding Veeva's expected future performance and, in particular, includes guidance, provided as of August 27, 2025, about Veeva's expected future financial results. Estimating guidance accurately for future periods is difficult. It involves assumptions and internal estimates that may prove to be incorrect and is based on plans that may change. Hence, there ...

"It's exciting to see our vision of connected software, data, and business consulting for life sciences becoming a reality," said CEO Peter Gassner. "I am especially excited about the power of Veeva AI and Veeva Data Cloud to enable transformational change for life sciences from clinical to commercial." Exhibit 99.1 FOR IMMEDIATE RELEASE Veeva Announces Fiscal 2026 Second Quarter Results Total Revenues of $789.1M, up 17% Year Over Year Subscription Services Revenues of $659.2M, up 17% Year Over Year PLEASAN ...

Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short- term price performance of a stock. While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' pr ...

Core Insights - Veeva Systems is hosting the Veeva R&D and Quality Summit on September 3-4, 2025, in Boston, featuring leaders from major biopharmaceutical companies like BeOne Medicines, Intercept Pharmaceuticals, Merck, and Pfizer to discuss advancements in clinical, regulatory, safety, and quality processes [1][5] Group 1: Event Highlights - The summit will showcase over 100 sessions focused on the latest advancements in life sciences, including strategies for accelerating development and manufacturing by connecting systems and processes [3] - Key topics include improving trial oversight and collaboration among sites, sponsors, and CROs [4] Group 2: Innovations and Technologies - Veeva will highlight its advancements in software, data, and business consulting, particularly the integration of Veeva AI into the Vault Platform, which provides secure access to data and workflows [2] - The event will feature discussions on how customers can leverage Veeva AI to create custom agents tailored to their needs [2] Group 3: Industry Engagement - The summit aims to foster an environment of openness where industry leaders can share experiences and ideas to expedite the delivery of medicines to patients [5] - More than 2,000 attendees are expected, all of whom are life sciences professionals [6] Group 4: Company Overview - Veeva Systems is recognized as a global leader in cloud software for the life sciences industry, serving over 1,000 customers, including large biopharmaceutical companies and emerging biotechs [7]

Company Performance - Veeva Systems closed at $279.18, with a daily increase of +1.36%, outperforming the S&P 500's gain of 0.32% [1] - The stock has decreased by 1.39% over the past month, underperforming the Medical sector's loss of 2.75% and the S&P 500's gain of 3.08% [1] Upcoming Earnings - The upcoming earnings report is scheduled for August 27, 2025, with projected EPS of $1.9, reflecting a 17.28% increase year-over-year [2] - Revenue is anticipated to be $767.61 million, indicating a 13.52% increase compared to the same quarter last year [2] Full Year Estimates - For the full year, earnings are expected to be $7.64 per share, marking a +15.76% change from the previous year [3] - Revenue for the year is projected at $3.1 billion, representing a +12.78% increase from last year [3] Analyst Estimates - Changes in analyst estimates are crucial as they reflect short-term business trends, with positive revisions indicating optimism about the business outlook [4] - The Zacks Rank system, which evaluates these estimate changes, currently ranks Veeva Systems at 2 (Buy) [6] Valuation Metrics - Veeva Systems has a Forward P/E ratio of 36.03, which is a premium compared to the industry average of 22.73 [7] - The company has a PEG ratio of 1.55, which is lower than the Medical Info Systems industry's average PEG ratio of 2.83 [7] Industry Ranking - The Medical Info Systems industry ranks in the top 30% of all industries, with a Zacks Industry Rank of 72 [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Core Insights - Veeva Systems Inc. (VEEV) is positioned for growth due to its strong product portfolio and solid first-quarter fiscal 2026 performance, despite concerns over rising operational costs [1][12]. Financial Performance - Veeva's shares have increased by 31.7% year-to-date, outperforming the industry growth of 19.9% and contrasting with the S&P 500's decline of 8.5% [2]. - The company has a market capitalization of $46.1 billion and anticipates a growth rate of 26.2% over the next five years, with a trailing four-quarter average earnings surprise of 10% [3]. Product and Service Developments - Veeva continues to drive the adoption of its next-gen Vault CRM, with 20 new customers, particularly from small and mid-sized biotech firms [5]. - The introduction of AI-driven innovations, such as CRM Voice Control and MLR Bot, aims to enhance efficiency and compliance [6]. - Veeva's Data Cloud solutions are gaining traction, with significant contracts and partnerships, including a long-term collaboration with Walgreens Boots Alliance [7][9]. Strategic Initiatives - The company has secured key deals, including Boehringer Ingelheim's migration to Veeva Vault CRM and partnerships to enhance generative AI capabilities [9]. - Veeva's first-quarter fiscal 2026 results exceeded expectations, driven by strong performance in subscription and professional services [10]. Cost Management - Operating costs have risen, with general and administrative expenses increasing by 12.3% year-over-year in the first quarter of fiscal 2026 [12]. - Total operating expenses increased by 9.4% year-over-year, with expectations for further increases due to employee compensation-related costs [13]. Future Outlook - The Zacks Consensus Estimate for fiscal 2026 earnings per share has increased by 3 cents to $7.64, with second-quarter revenue estimates indicating a 13.5% improvement year-over-year [14].